Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Statement re. Suspension

9 Jul 2008 15:45

RNS Number : 7132Y
Sareum Holdings PLC
09 July 2008
 



9 July 2008

Sareum Holdings plc ("Sareum" or "the Company")

Suspension of trading of Sareum shares on AIM

On 19 June 2008, the Company announced that the board of Sareum ("the Board") believed that the Company needed to undertake a strategic transaction and that should the Board decide within a short timescale that a strategic transaction is not achievable, the Board would take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

Since 19 June, the Board has continued to progress discussions with a number of parties, including in respect of a possible reverse transaction, but at this time does not consider that it will be able to conclude a strategic transaction for several months.  Further, in the current difficult financial markets, the Board does not consider that it will be possible to achieve a significant fundraising to enable the Company to continue operations in its present form although the Board may still need to secure interim funding to enable it to complete a strategic transaction.

In view of the uncertainty that the Company will be able to raise funds or complete a strategic transaction, the Board has requested a suspension of trading in its shares on AIM.

Contacts:

 

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton UK LLP

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SRSSSEFLUSASEEW
Date   Source Headline
12th Sep 20227:00 amRNSSareum notes FDA approval of first TYK2 Inhibitor
28th Jul 20227:00 amRNSCTA application to MHRA and Corporate Update
4th Jul 20227:00 amRNSSareum notes GSK's completed acquisition of Sierra
26th Apr 20227:00 amRNSSareum to Present at BioTrinity 2022 Conference
13th Apr 20224:00 pmRNSSareum notes acquisition of Sierra Oncology by GSK
13th Apr 202211:05 amRNSSecond Price Monitoring Extn
13th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSEuropean Patent Granted for Sareum’s SDC-1802
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:36 pmRNSPrice Monitoring Extension
6th Apr 20222:06 pmRNSSecond Price Monitoring Extn
6th Apr 20222:00 pmRNSPrice Monitoring Extension
16th Mar 20227:00 amRNSSDC-1801: Preclinical Toxicology Report Received
9th Mar 202211:06 amRNSSecond Price Monitoring Extn
9th Mar 202211:00 amRNSPrice Monitoring Extension
28th Feb 20223:50 pmRNSResults of EGM
21st Feb 20227:00 amRNSHalf-year Report
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSPublication of Circular; Notice of General Meeting
28th Jan 20228:11 amRNSCorrection - Issue of Warrants
28th Jan 20227:00 amRNSIssue of Warrants
25th Jan 20227:00 amRNSSareum to Participate in Edison Open House Event
17th Dec 20217:00 amRNSSubscription to raise £1.63m to progress SDC-1801
16th Dec 20214:21 pmRNSResult of AGM
16th Dec 20217:00 amRNSAGM Statement
15th Dec 20217:00 amRNSIntention to grant notice - EU patent for SDC-1802
7th Dec 20217:00 amRNSAGM Update
23rd Nov 202112:57 pmRNSDirector/PDMR Shareholding
19th Nov 20217:00 amRNSNotice of AGM
3rd Nov 20213:00 pmRNSExercise of Share Options and Director Dealings
29th Oct 20217:00 amRNSAppointment of Joint Corporate Broker
25th Oct 20217:00 amRNSSareum: Final Results for Year Ended 30 June 2021
21st Oct 20218:32 amRNSCorrection - Notice of Results
21st Oct 20217:00 amRNSNotice of Results and Investor Presentation
7th Oct 202110:42 amRNSUS Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
29th Sep 202110:46 amRNSReference to SRA737 Timeline at Cantor Conference
19th Aug 20217:00 amRNSTrading Statement
9th Aug 20211:26 pmRNSSubscription to raise £1,000,000
6th Aug 20217:19 amRNSSRA737 update
30th Jul 20217:00 amRNSUS Patent Notice of Allowance for SDC-1802
19th Jul 20212:05 pmRNSSecond Price Monitoring Extn
19th Jul 20212:01 pmRNSPrice Monitoring Extension
19th Jul 202111:13 amRNSSubscription to raise £1,000,000
14th Jul 20217:00 amRNSExercise of Warrants and Total Voting Rights
1st Jul 20217:00 amRNSCovid-19 Research Project Results
24th Jun 20212:05 pmRNSSecond Price Monitoring Extn
24th Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20218:00 amRNSSareum to Present at BioTrinity 2021 Conference
17th Jun 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.